Skip to main content
Premium Trial:

Request an Annual Quote

Hitachi, French Cancer Center Partner on AI-Focused Research

NEW YORK – Hitachi and Centre Léon Bérard (CLB), a cancer center in Lyon, France, said Thursday that they have partnered on research and development aimed at improving the efficiency and efficacy of cancer diagnosis and treatment.

As part of the agreement, they have jointly established a new research laboratory. The Hitachi Lyon Lab, housed at CLB, will study novel ways to detect cancer by applying artificial intelligence to medical imaging and to predict response to radiation therapy using genomic and transcriptomic data. 

The partners said they would apply CLB's clinical expertise and patient data and Hitachi's know-how in diagnostic imaging and AI to develop diagnostic imaging technologies to detect cancer sites and to help radiologists improve diagnosis from CT and MRI scans. In addition, they plan to identify biomarkers from genomic data to predict response to radiation treatment and prognoses after such treatment.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.